Bacterial resistance to antibiotics has been increasing day by day. Many superbugs are emerging in current times, paving the way for the discovery of new molecules that could fight against these resistant bacteria. Many of these bacteria are seen commonly in ICU settings paving the way for many critical infections such as sepsis, UTI, pyuria, septicemia, and others. Many molecules have been discovered to deal with such resistant bacteria, but a recent one Arbekacin is said to be a standout from others.
Arbekacin is an aminoglycoside which acts against methicillin-resistant Staphylococcus aureus (MRSA). In recent studies, it is found to impart equal efficacy as other aminoglycosides along with label expansion of efficacy against gram-negative bacteria. In this exclusive interview, important aspects about different superbugs along its effect on critical infections in ICU setup has been…
